Zhengye Biotechnology Holding Limited: Fiscal Year 2025 Financial Results and Growth Strategies
Zhengye Biotechnology Holding Limited, a leading veterinary vaccine manufacturer in China, recently announced its financial results for the fiscal year 2025. Despite challenges in the hog market and government policies affecting swine vaccine demand, the company focused on its strategy and saw growth in other vaccine segments, particularly sheep vaccines. Zhengye also made progress in expanding its international presence by advancing vaccine registrations in markets like Egypt, Pakistan, and Vietnam.
The company continued to prioritize research and development, achieving regulatory milestones and securing new product approvals across various animal species. With a strengthened capital base from its Nasdaq listing, Zhengye aims to invest in research and development, expand its product portfolio, and support future growth initiatives. The company is optimistic about the gradual recovery in China's swine market and plans to deepen customer engagement, strengthen its product offerings, and explore opportunities in the companion animal sector.
In terms of financial performance, Zhengye reported a decrease in net revenue, cost of revenue, and gross profit for the fiscal year 2025. Operating expenses increased, leading to a net loss compared to the previous year's net income. The company ended the year with a stronger cash position, providing a foundation for future investments and growth initiatives.
As of December 31, 2025, Zhengye had cash of RMB50.3 million and reported net cash provided by operating activities, net cash used in investing activities, and net cash provided by financing activities. The company remains committed to its long-term growth strategy and acknowledges the support of its shareholders, customers, and partners in navigating industry challenges and laying a foundation for future success.